Skip to main content
Premium Trial:

Request an Annual Quote

UK Startup Paradigm Therapeutics Signs Drug Target Deal with Medavir

 

NEW YORK, Dec. 13 - Paradigm Therapeutics, of Cambridge, UK, has signed a three-year collaboration with Swedish biopharma Medavir, to discover new protease drug targets, the company said Friday.

 

Paradigm, a spinout from the Universityof Cambridge, uses transgenic mouse technology, along with bioinformatics and other molecular biology methods, to determine the biological function of novel human proteins encoded by the genome, in order to find new drug leads. Earlier this week, the company raised £12 million ($19.1 million) in a second round of private financing.

 

Medavir, of Huddinge, Swedenand Cambridge, UK, will offer its protease inhibitor drug discovery know-how, and its compound libraries, to the collaboration.

 

The partners plan to identify up to six novel proteases, and develop small-molecule protease inhibitor drugs, for either commercialization or out licensing.   They did not disclose financial terms of the agreement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.